Slides
Page 1
S E P T E M B E R 2 0 2 5 Writing the Future Emily Leproust, CEO and Cofounder
Page 2
| TWIST BIOSCIENCE Legal Disclaimers | PROPRIETARY2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward- looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, annual financial guidance for fiscal 2025 and for the fourth quarter of fiscal 2025, statements regarding Twist Bioscience's path to profitability, future growth, expansion, market share gains and Twist Bioscience’s other expectations regarding its future operations plans and financial performance, ability and timing to increase gross margin, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist Bioscience’s costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; risks associated with the spin out of Atlas Data Storage and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in TwistBioscience’s Annual Report on Form 10-K filed with the SEC on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. The presentation also contains supplemental financial information determined by methods other than in accordance with U.S. generally accepted accounting principles ("GAAP"). A reconciliation of these non-GAAP financial measures may be found starting on page 29 of this presentation.
Page 3
| TWIST BIOSCIENCE RNA PROTEINS DNA | PROPRIETARY and CONFIDENTIAL3 One chip Unprecedented scale, many opportunities for cost efficient expansion DNA on Silicon Platform MORE Products MORE Customers MORE Applications MORE Markets
Page 4
| TWIST BIOSCIENCE 1 2 3 Clear Focus: Life Sciences Tools 4 PROVEN PLATFORM Disruptive products and services COMMERCIAL EXECUTION Inside sales, digital marketing, account management, B2B, eCommerce STRONG FOUNDATION SynBio Write NGS Read Biopharma Solutions
Page 5
| TWIST BIOSCIENCE $63.7 $66.9 $71.5 $75.3 $81.5 $84.7 $88.7 $92.8 $96.1 FY23Q3 FY23Q4 FY24Q1 FY24Q2 FY24Q3 FY24Q4 FY25Q1 FY25Q2 FY25Q3 $ Millions $58.3M $57.4M $63.3M $64.4M $64.1M $60.7M $64.6M $67.4M $65.5 ($29.6M) ($26.4M) ($27.8M) ($26.8M) ($22.0M) ($17.0M) ($16.3M) ($14.8M) ($8.0M) Adj. SG&A + Adj. R&D* Adj EBITDA**: 40.5% GM 41.0% GM 43.3% GM 45.1% GM 49.6% GM 53.4% GM 34.4% GM 36.6% GM 48.3% GM * Adjusted SG&A and Adjusted R&D expenses are defined as SG&A and R&D expenses adjusted to exclude depreciation and amortization and stock-based compensation expense. This non-GAAP measure is not in accordance with, or an alternative for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles. See page 10 for Adjusted SG&A and Adjusted R&D reconciliation. ** See page 9 for ADJ EBITDA reconciliation Adjusted EBITDA Progress Toward Break-even | PROPRIETARY5
Page 6
| TWIST BIOSCIENCE Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun 2019 $ in Millions $11.5 $13.6 $17.2 $19.3 $21.2 $32.4 $28.2 $31.2 $35.0 $38.0 $42.0 $48.1 $56.1 $57.3 $54.2 $60.2 $63.7 $66.9 Biopharma NGS SynBio Strong Quarterly Revenue Growth $84.7 | PROPRIETARY6 2020 2021 2022 2023 2024 $15.7$13.6 $71.5 $75.3 $81.5 $88.7 2025 $92.8 $96.1
Page 7
| TWIST BIOSCIENCE Strong Foundation and Strategic Moat in Place | PROPRIETARY7 #4 Digitized operational workflow and supply chain #5 Standardized and automated processes #6 $1B infrastructure investment underway #7 Relentless focus on innovation #8 Exceptional research and regulatory scale #9 Diverse team expertise, unique culture #1 Deep understanding of customer needs #2 Multiple efficient and effective channels #3 Industrialized customization of biology
Page 8
Writing the Future
Page 9
| TWIST BIOSCIENCE (In Thousands) Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 GAAP Net Income $(57,395) $(46,243) $(43,008) $(45,492) (85,571) $(34,655) $(31,594) $(39,328) 20,390 Add (Deduct) Adjustments: Interest Income (3,968) (3,893) (4,120) (3,941) (3,663) (3,620) (3,240) (2,801) (2,690) Income Tax Expense 622 (221) 120 345 191 (96) 97 175 191 Depreciation and Amortization 8,490 8,500 8,171 8,304 8,301 6,656 6,382 6,402 6,065 EBITDA $(52,251) (41,857) (38,837) $(40,784) (80,742) $(31,715) (28,355) $(35,552) 23,956 Add (Deduct) Adjustments: Other Income/Expense, Net (40) 246 31 199 121 2,327 93 394 836 Stock-based Compensation Expense 10,597 11,747 11,020 13,824 13,734 12,347 11,991 20,328 16,057 Gain on sale of business — — — — — — — — (48,847) Change in fair of contingent considerations and holdbacks (582) — — — — — — — — Restructuring costs 9,052 332 — — — — — — — Impairment of long-lived assets 3,620 3,165 — — 44,930 — — — — Adjusted EBITDA $(29,604) $(26,367) $(27,786) $(26,761) (21,957) $(17,042) $(16,271) $(14,830) $(7,998) | PROPRIETARY9 Adjusted EBITDA Reconciliation
Page 10
| TWIST BIOSCIENCE (In Millions) Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 R&D Expenses — GAAP $24.5 $23.7 $23.1 $24.1 $22.5 $21.1 $21.3 $23.9 $18.0 Adjusted to exclude: Depreciation and Amortization 1.2 0.8 0.9 0.9 0.9 0.5 0.4 0.4 0.2 Stock-based Compensation Expense 3.3 3.1 2.8 3.4 2.4 2.6 2.7 3.5 0.9 Adjusted R&D Expenses $20.0 $19.9 $19.4 $19.9 $19.2 $18.1 $18.1 $20.0 $16.9 SG&A Expenses — GAAP $46.1 $47.4 $52.8 $55.6 $56.8 $53.1 $56.2 $63.7 $63.4 Adjusted to exclude: Depreciation and Amortization 1.8 1.9 1.7 1.7 1.6 1.8 1.6 1.6 1.7 Stock-based Compensation Expense 6.0 8.0 7.3 9.4 10.3 8.8 8.0 14.7 13.1 Adjusted SG&A Expenses $38.3 $37.5 $43.9 $44.5 $44.9 $42.6 $46.5 $47.4 $48.6 Adjusted R&D + SG&A Expenses $58.3 $57.4 $63.3 $64.4 $64.1 $60.7 $64.6 $67.4 $65.5 | PROPRIETARY10 Adjusted R&D and SG&A Expenses Reconciliation